It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Prolyl 4-hydroxylases (P4Hs) are a family of key modifying enzymes in collagen synthesis. P4Hs have been confirmed to be closely associated with tumor occurrence and development. However, the expression of P4Hs in head and neck cancer (HNSC) as well as its relationship with prognosis and tumor immunity infiltration has not yet been analyzed. We investigated the transcriptional expression, survival data, and immune infiltration of P4Hs in patients with HNSC from multiple databases. P4H1-3 expression was significantly higher in HNSC tumor tissues than in normal tissues. Moreover, P4HA1 and P4HA2 were associated with tumor stage, patient prognosis, and immune cell infiltration. P4HA3 was related to patient prognosis and immune cell infiltration. Correlation experiments confirmed that P4HA1 may serve as a prognosis biomarker and plays a role in the progression of nasopharyngeal carcinoma. These findings suggest that P4HA1-3 may be a novel biomarker for the prognosis and treatment of HNSC, which is expected to support the development of new therapies for patients with head and neck tumors and improve patient outcomes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Affiliated Hospital of Southwest Medical University, Department of Oncology, Luzhou, China (GRID:grid.488387.8)
2 The Affiliated Hospital of Southwest Medical University, Department of Cardiology, Luzhou, China (GRID:grid.488387.8)
3 The Affiliated Hospital of Southwest Medical University, Department of Pathology, Luzhou, China (GRID:grid.488387.8)
4 The Affiliated Hospital of Southwest Medical University, Department of Bone and Joint, Luzhou, China (GRID:grid.488387.8)
5 The Affiliated Hospital of Southwest Medical University, Department of Oncology, Luzhou, China (GRID:grid.488387.8); The Affiliated Tianfu Hospital of Southwest Medical University, Department of Oncology, Meishan, China (GRID:grid.410578.f) (ISNI:0000 0001 1114 4286)